Combination Therapy with Aromatase Inhibitors in Postmenopausal Breast Cancer

Combination therapy, utilizing Aromatase Inhibitors (AIs) alongside targeted agents, has emerged as one of the promising approaches in the treatment of hormone-sensitive breast cancer in postmenopausal women. This is because endocrine or hormonal therapy was found effective in hormone-sensitive breast cancer for a considerable period of time.